ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience...

https://www.irishtimes.com/business/technology/atxa-therapeutics-looks-to-raise-30m-to-secure-regulatory-approval-1.4314023

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a preclinical model of pulmonary...

The companies driving Ireland's entrepreneurial edge. ATXA Therapeutics Ltd is delighted to be recognised amongst such a fantastic list...

We’re here at the ERS Congress 2019 where we will be presenting the our preclinical findings of NTP42 for the treatment of PAH. Please...

We're here! Drop by the Poster Area for the session on "Pulmonary Arterial Hypertension ‑ Treatments" and talk to us about our...

ATXA Therapeutics and PAH-Hope team members, Prof. Therese Kinsella & Dr. Helen Reid are looking forward to the ESC Congress 2019 next...

Use the link below to read or download ATXA Therapeutics published article on the expression and regulation of thromboxane receptors in...

ATXA Therapeutics, along with members of the academic research group of CSO Prof. Therese Kinsella at University College Dublin, have...

PAH-HOPE CSO Prof. Therese Kinsella is in Brussels meeting fellow entrepreneurs in the EIC community at SME Phase 2 Coordinators Welcome...